Cargando…

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study

PURPOSE: To compare the efficacy and tolerability of mirabegron and solifenacin in pediatric patients with idiopathic overactive bladder (OAB) and to identify factors affecting OAB symptom improvement after treatment. MATERIALS AND METHODS: We retrospectively reviewed 103 patients (5–15 years old) w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seong Cheol, Park, Myungchan, Chae, Chongsok, Yoon, Ji Hyung, Kwon, Taekmin, Park, Sejun, Moon, Kyung Hyun, Cheon, Sang Hyeon, Park, Sungchan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100008/ https://www.ncbi.nlm.nih.gov/pubmed/33834641 http://dx.doi.org/10.4111/icu.20200380

Ejemplares similares

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study
por: Lee, Sang Don, et al.
Publicado: (2017)

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study
por: Tang, Qing-lai, et al.
Publicado: (2022)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
por: Kwon, Taekmin, et al.
Publicado: (2017)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
por: Hsiao, Sheng-Mou, et al.
Publicado: (2022)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Outcomes of extracorporeal shock wave lithotripsy for ureteral stones according to ESWL intensity
por: Yoon, Ji Hyung, et al.
Publicado: (2021)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction
por: Yoon, Ji Hyung, et al.
Publicado: (2018)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Loupe-Assisted Vasovasostomy Using a Prolene Stent: A Simpler Vasectomy Reversal Technique
por: Jeon, Jong Chul, et al.
Publicado: (2017)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
por: Choi, Hoon, et al.
Publicado: (2018)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
por: Mueller, Elizabeth R., et al.
Publicado: (2019)

Mass size is a major predictor of hypertensive attack during surgery in patients with paraganglioma of retroperitoneum
por: Yoon, Ji Hyung, et al.
Publicado: (2022)

Efficacy of Holmium Laser Enucleation of the Prostate in Patients with a Small Prostate (≤30 mL)
por: Park, Sejun, et al.
Publicado: (2017)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
por: Tijnagel, Marloes J., et al.
Publicado: (2017)

Study of mirabegron and solifenacin in the improvement of catheter-related bladder discomfort in patients undergoing transurethral resection: A case–control study
por: Fan, Bohan, et al.
Publicado: (2022)

Clinicopathological Characteristics of Urinary Bladder Tumors in Korean Patients 20 Years or Younger
por: Kim, Seong Cheol, et al.
Publicado: (2018)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o4cgn88d3ohsuv0e3a16usclso